Prader-Willi syndrome

News

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Neurocrine Biosciences has agreed a $2.9bn deal to buy Soleno Therapeutics and its treatment for a rare, genetic form of severe obesity.

News

Acadia, Harmony record late-stage rare disease failures

Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.

News

FDA clears first treatment for Prader-Willi syndrome

Soleno Therapeutics' Vykat XR has become the first FDA-approved treatment for excessive eating in rare disorder Prader-Willi syndrome.

Views & Analysis

Bringing social media listening into R&D

After her daughter was diagnosed with Prader-Willi syndrome, Maria Picone used social media listening and AI analytics to find out the best ways to manage the rare disease.

Views & Analysis

Millendo’s Julia Owens on leadership in rare diseases

Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome.

News

DNA helix in a futuristic concept of the evolution of science and medicine.

Zafgen ends development of Prader-Willi drug

Share price plummets after biotech said drug is unsafe.

Neurocrine pays $2.9bn for Soleno and extreme hunger drug

Acadia, Harmony record late-stage rare disease failures

FDA clears first treatment for Prader-Willi syndrome

Bringing social media listening into R&D

Millendo’s Julia Owens on leadership in rare diseases

Zafgen ends development of Prader-Willi drug

Zymeworks cuts deal to buy Theravance for $929m in cash

Discover a new era of healthcare panel engagement: Grounded ...

Prader-Willi syndrome

Editor's Picks